SCYNEXIS Inc (SCYX) stock
Close on Nov 13, 2026Market cap $31.94MP/E –Yield –
SCYNEXIS Inc grew revenue 544.0% to $18.88M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $31.94M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $31.94M
- P/E ratio
- –
- Price to sales
- 1.69
- Price to book
- 0.54
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $18.88M
- Net income
- -$10.10M
- EPS, diluted
- -$1.50
- Book value per share
- $4.99
- Diluted shares
- 12M
Trading
- Previous close
- $3.33
- Open
- $3.35
- Day's range
- $3.10 – $3.35
- Volume
- 64,372
- Average volume (20 days)
- 64,017
- Beta (5 years)
- 1.58
- 52-week range
- $3.10 – $9.12
- RSI (14 days)
- 31.4
- Volatility (1 year)
- 75.0%
- Relative volume
- 0.29×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SCYX | S&P 500 | Difference | SCYX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.5% | -3.0% | −16.5 pts | ||
| 3 months | -37.3% | -2.8% | −34.5 pts | ||
| Year to date | -36.6% | +11.5% | −48.0 pts | ||
| 1 year | -32.0% | +13.5% | −45.5 pts | ||
| 3 years | -76.6% | +77.7% | −154.3 pts | -38.4% | +21.1% |
| 5 years | -92.6% | +72.6% | −165.2 pts | -40.5% | +11.5% |
| 10 years | -98.9% | +308.2% | −407.1 pts | -36.3% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Scynexis filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- Update
About Scynexis
Pharmaceutical Preparations
SCYNEXIS, Inc. is a biotechnology company that develops treatments for severe diseases, focusing on drug-resistant and difficult-to-treat fungal infections. The company creates therapies using its proprietary platform of triterpenoid antifungal agents known as fungerps. Its lead commercialized product is ibrexafungerp, marketed as BREXAFEMME for vaginal yeast infections and licensed to GSK. SCYNEXIS also advances clinical candidates such as SCY-247, an antifungal evaluated in oral and intravenous formulations for invasive candidiasis. Its therapies target hospitalized and immunocompromised patients treated by infectious disease specialists, oncologists, and critical care physicians at major medical centers.
Company profile, executives and historyScynexis stock: common questions
What is Scynexis's stock price?
SCYX closed at $3.21 on Nov 13, 2026, down 3.60% on the day. Over the past 52 weeks it traded between $3.10 and $9.12.
What is Scynexis's market cap?
Scynexis was worth $31.94M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SCYX's P/E ratio?
Scynexis lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.50), so it has no meaningful P/E ratio.
How much revenue does Scynexis make?
Scynexis reported revenue of $18.88M for the twelve months to Sep 30, 2026, up 544.0% from a year earlier.
Does Scynexis pay a dividend?
No. Scynexis has not paid a cash dividend over the last twelve months.
How has SCYX stock performed over the past year?
Including dividends, SCYX returned -32.0% over the past year, against +13.5% for the S&P 500.
How many SCYX shares are sold short?
0M shares were sold short at the latest FINRA report, 6.02% of the float, or 5.5 days of average trading volume.
Who are Scynexis's competitors?
Companies most similar to Scynexis by business, industry and size include ZNTL, EVFM, QURE, SPRO, ARCT.
See a number that looks wrong?